

Therapeutic Evaluation of DA-7503, a Tau Aggregation Inhibitor,
Alone and in Combination with Lecanemab in Tauopathy & AD Models


P3-01 # 4668



Hyangsoo Lee^a, **Jee-Heun Kim^a**, Sungsu Lim^b, Jongho Cho^a, Jun-Hwan Moon^a, Yun Kyung Kim^b, Mi-Kyung Kim^a, Ae Nim Pae^b.
^aDong-A ST, Yongin-si, Republic of Korea, ^bBrain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea

Introduction

- ❖ **DA-7503** is a **small molecule tau aggregation inhibitor** that **reversibly binds** to tau via **covalent** bonding.
- ❖ **DA-7503**, a **first-in-class** potential clinical candidate for Alzheimer's disease (AD) under early clinical development.
- ❖ In **Phase 1** study, it was demonstrated that the **brain exposure** necessary for efficacy regarding **tau pathology** and **behavioral indicators** of memory and cognitive function can be reached.
- ❖ **DA-7503** engages **tau cysteines**, and thereby **disrupts di-sulfide bond-dependent oligomerization** and **inhibits phosphorylation of pathological tau¹⁻³**.



Conclusion

- ❖ **DA-7503** **dose-dependently** improves cognitive and motor function and suppresses tau phosphorylation, oligomerization and aggregation in Tau^{P301L}-BiFC mice, with clear efficacy even at **low dose of 1-3 mg/kg**.
- ❖ **DA-7503** reduces both tau and amyloid-β pathology, and in combination with Lecanemab achieves the greatest overall reduction in these pathologies, supporting **dual-targeting as a disease-modifying strategy in AD**.
- ❖ **DA-7503** was proven to be taken **orally once a day**, and was **well tolerated** in **Phase 1** clinical trial in Korea (NCT06391827).
- ❖ The results provide evidence supporting further clinical development as **monotherapy** and **combination therapy** with a current standard of care for AD.


Contact

• Website: <http://en.donga-st.com/Main.da>
• Email: anpae@kist.re.kr; kmk@donga.co.kr; jeeheun.kim@donga.co.kr (Jee-Heun Kim)




Dong-A ST Co., Ltd. has exclusive global rights of development and commercialization for DA-7503. This research was supported by a grant of the Korea Dementia Research Project through the Korea Dementia Research Center (KDRC), funded by the Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea (Grant number : RS-2024-00438603).
Reference: 1) AAIC2022 #6119; 2) AAIC2024 #84642; 3) AAIC2025 #100012

Low-Dose, Dose-Dependent Efficacy of DA-7503 in Tau^{P301L}-BiFC Mice



• **DA-7503** dose-dependently improves cognitive and motor performance while robustly suppressing tau phosphorylation and oligomerisation in Tau^{P301L}-BiFC mice across cortical and hippocampal regions and multiple biochemical fractions, with significant efficacy evident even at low doses of 1-3 mg/kg

Dual-Target Combination of DA-7503 and Lecanemab on Tau and Amyloid-β Pathology



• **DA-7503, alone or in combination with Lecanemab, reduced tau aggregation, tau hyperphosphorylation, and amyloid-β pathology, with the combination achieving the largest and most consistent overall reductions in both tau and amyloid, supporting dual-targeting as a promising disease-modifying strategy in AD.**